Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isotechnika enrolls last patient in transplantation drug trial
Of the 332 patients enrolled, 148 patients have already completed the required six months of treatment. The company expects to have the last patient complete the six months
Of the 332 patients enrolled, 148 patients have already completed the required six months of treatment. The company expects to have the last patient complete the six months
KP-1461 id a viral decay acceleration agent, inducing mutations within the HIV genome leading to degraded viral fitness and viral collapse. This is contrast to most HIV treatments
<p>The double-blinded, placebo-controlled, dose-ranging study enrolled 281 patients with a BMI ranging from 30-40 at 20 at clinical centers across the US. Subjects were randomized into one of
<p>An analysis published in the New England Journal of Medicine in May found that Avandia increased the risk of heart attack by 43% and the risk of heart
Actavis’ nifedipine extended-release tablets are the generic equivalent of Bayer’s Adalat CC tablets and are available in 30mg and 60mg strengths. They can be used alone or in
The company says results of the trials show that topically applied REP8839 appears safe, well-tolerated and associated with low systemic exposure, or drug absorption into the bloodstream, which
The drug, SKP-1041, is a new controlled release formulation of a non-benzodiazepine hypnotic agent which utilizes UK-based SkyePharma’s Geoclock technology. As part of the agreement, SkyePharma will formulate
The submission is based upon data from the phase III SPARC trial comparing satraplatin plus prednisone to placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC)
This is the second milestone reached in the collaboration, in which Galapagos has agreed to discover and validate novel drug targets for Wyeth. Under the terms of the
The trial began with the dosing of the first patient, the companies said. The study is designed to enroll over 200 patients with relapsing-remitting MS who have failed